The troubled drugmaker takes another plunge as it reduces guidance. Here’s a quick survey of the firms that are taking a bath and those that look like geniuses.
A bid by Pfizer for Allergan would be the year’s biggest deal; Valeant distances itself from Philidor; Budget deal passed in Congress.